Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by narmacon Dec 15, 2022 6:56am
114 Views
Post# 35172504

RE:RE:One more thing ......

RE:RE:One more thing ......After reading the BTI December presentation for the second time it comes to mind that we have a potential timeline of activity which again seems to have little catalyst by way of hard data which would allow the market to move our stock price up over the coming 12+ months. There is no business model included to show the dilution we can expect to be carried out due to the desribed activity going forward. If what we know as being a solid assumption in that research takes lots of money then we should expect lots of dilution around this new company where the financiers will of course continually take the vast majority of ownership going forward the next few years. 

JD may be onto something when he feels that xB3 will be the fuel for Midatechs push around their technology.  We are not allowed to know the true mandate. Then again,,why merge with BTI,,,and,,if BTI couldnt sell our xB3 technology even on the xB3-001 program how will Midatech do so?? 
<< Previous
Bullboard Posts
Next >>